Inflammatory Microenvironment in Early Non-Small Cell Lung Cancer: Exploring the Predictive Value of Radiomics.

biomarkers inflammasomes microenvironment radiomic features stage I NSCLC

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
08 Jul 2022
Historique:
received: 10 06 2022
revised: 30 06 2022
accepted: 05 07 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 28 7 2022
Statut: epublish

Résumé

Patient prognosis is a critical consideration in the treatment decision-making process. Conventionally, patient outcome is related to tumor characteristics, the cancer spread, and the patients' conditions. However, unexplained differences in survival time are often observed, even among patients with similar clinical and molecular tumor traits. This study investigated how inflammatory radiomic features can correlate with evidence-based biological analyses to provide translated value in assessing clinical outcomes in patients with NSCLC. We analyzed a group of 15 patients with stage I NSCLC who showed extremely different OS outcomes despite apparently harboring the same tumor characteristics. We thus analyzed the inflammatory levels in their tumor microenvironment (TME) either biologically or radiologically, focusing our attention on the NLRP3 cancer-dependent inflammasome pathway. We determined an NLRP3-dependent peritumoral inflammatory status correlated with the outcome of NSCLC patients, with markedly increased OS in those patients with a low rate of NLRP3 activation. We consistently extracted specific radiomic signatures that perfectly discriminated patients' inflammatory levels and, therefore, their clinical outcomes. We developed and validated a radiomic model unleashing quantitative inflammatory features from CT images with an excellent performance to predict the evolution pattern of NSCLC tumors for a personalized and accelerated patient management in a non-invasive way.

Identifiants

pubmed: 35884397
pii: cancers14143335
doi: 10.3390/cancers14143335
pmc: PMC9323656
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Italian Association for Cancer Research
ID : IG-19803
Organisme : Italian Association for Cancer Research
ID : IG-23670
Organisme : Italian Association for Cancer Research
ID : ID-26665
Organisme : Progetti di Rilevante Interesse Nazionale
ID : PRIN2017E5L5P3
Organisme : Progetti di Rilevante Interesse Nazionale
ID : PRIN20177E9EPY
Organisme : Ministero della Salute
ID : GR-2019-12369646
Organisme : European Research Council
ID : 853057-InflaPML
Pays : International

Références

Front Comput Neurosci. 2020 Apr 16;14:32
pubmed: 32372938
Cell. 2010 Mar 19;140(6):821-32
pubmed: 20303873
Expert Rev Anticancer Ther. 2018 Jan;18(1):63-70
pubmed: 29168933
Curr Pharm Des. 2017;23(32):4893-4905
pubmed: 28606052
Cancer Cell. 2016 Nov 14;30(5):668-681
pubmed: 27846389
JTO Clin Res Rep. 2021 Mar 24;2(5):100165
pubmed: 34590017
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Hum Immunol. 1983 Oct;8(2):123-39
pubmed: 6417067
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
Cancer Control. 2021 Jan-Dec;28:1073274820985786
pubmed: 33567876
Respir Res. 2014 Feb 24;15:23
pubmed: 24564813
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Br J Cancer. 2019 Jan;120(1):45-53
pubmed: 30413828
J Biomed Sci. 2019 Oct 20;26(1):78
pubmed: 31629410
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Ann Oncol. 2016 Sep;27(suppl 5):v1-v27
pubmed: 27664245
Cancers (Basel). 2021 May 11;13(10):
pubmed: 34064909
Lancet Oncol. 2018 Sep;19(9):1180-1191
pubmed: 30120041
J Thorac Oncol. 2014 Oct;9(10):1434-42
pubmed: 25170646
Med Oncol. 2020 May 18;37(6):54
pubmed: 32424733
Lab Invest. 2017 Jan;97(1):24-33
pubmed: 27869796
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
BMJ Open. 2015 Dec 23;5(12):e009419
pubmed: 26700282
Front Immunol. 2019 Feb 15;10:193
pubmed: 30828330
Lung Cancer Manag. 2021 Feb 19;10(2):LMT46
pubmed: 34084212
Immunobiology. 1991 Sep;183(1-2):79-87
pubmed: 1834546
Nat Rev Clin Oncol. 2015 Mar;12(3):132-4
pubmed: 25687910
Cancer Lett. 2017 Feb 28;387:61-68
pubmed: 26845449

Auteurs

Mariasole Perrone (M)

Department of Medical Sciences, Section of Experimental Medicine, Laboratory for Technologies of Advanced Therapies, University of Ferrara, 44121 Ferrara, Italy.

Edoardo Raimondi (E)

Radiology Division, SS.ma Annunziata Hospital, Azienda USL di Ferrara, 44121 Ferrara, Italy.

Matilde Costa (M)

Tecnologie Avanzate TA Srl, Research & Development, 33100 Udine, Italy.

Gianluca Rasetto (G)

Radiology Division, SS.ma Annunziata Hospital, Azienda USL di Ferrara, 44121 Ferrara, Italy.

Roberto Rizzati (R)

Radiology Division, SS.ma Annunziata Hospital, Azienda USL di Ferrara, 44121 Ferrara, Italy.

Giovanni Lanza (G)

Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.

Roberta Gafà (R)

Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.

Giorgio Cavallesco (G)

Department of Medical Sciences, Section of General and Thoracic Surgery, Sant'Anna University Hospital, 44121 Ferrara, Italy.

Nicola Tamburini (N)

Department of Medical Sciences, Section of General and Thoracic Surgery, Sant'Anna University Hospital, 44121 Ferrara, Italy.

Pio Maniscalco (P)

Department of Medical Sciences, Section of General and Thoracic Surgery, Sant'Anna University Hospital, 44121 Ferrara, Italy.

Maria Cristina Mantovani (MC)

Department of Medical Sciences, Section of Experimental Medicine, Laboratory for Technologies of Advanced Therapies, University of Ferrara, 44121 Ferrara, Italy.

Umberto Tebano (U)

Department of Radiation Oncology and Nuclear Medicine, AULSS 9 Scaligera, 37100 Verona, Italy.

Manuela Coeli (M)

Department of Radiation Oncology and Nuclear Medicine, AULSS 9 Scaligera, 37100 Verona, Italy.

Sonia Missiroli (S)

Department of Medical Sciences, Section of Experimental Medicine, Laboratory for Technologies of Advanced Therapies, University of Ferrara, 44121 Ferrara, Italy.

Massimo Tilli (M)

Radiology Division, SS.ma Annunziata Hospital, Azienda USL di Ferrara, 44121 Ferrara, Italy.

Paolo Pinton (P)

Department of Medical Sciences, Section of Experimental Medicine, Laboratory for Technologies of Advanced Therapies, University of Ferrara, 44121 Ferrara, Italy.

Carlotta Giorgi (C)

Department of Medical Sciences, Section of Experimental Medicine, Laboratory for Technologies of Advanced Therapies, University of Ferrara, 44121 Ferrara, Italy.

Francesco Fiorica (F)

Department of Radiation Oncology and Nuclear Medicine, AULSS 9 Scaligera, 37100 Verona, Italy.

Classifications MeSH